Earlier this year, I attended an agility trial in New Jersey that was raising money for canine cancer research. Decorating the arena were pictures of dogs who had cancer at some point in their lives. There were more than 100 photo montages covering every inch of free space.
During an intermission tribute, handlers were asked to raise their hand if they ever had a dog affected by cancer. I was shocked to see well more than half the audience with their hand up and soon learned that canine cancer effects one out of every three dogs.
Since then, two of my friends found tumors on their dogs, one benign and one malignant. Thankfully, both were successfully removed, but the topic has stayed on my mind. So I was excited to hear that this month the U.S. Food and Drug Administration approved the first drug developed specifically for the treatment of canine cancer. Palladia, an oral drug, works by cutting off the blood supply to mast cell tumors, the second most common tumor in dogs.
Palladia will be available next year through veterinary oncologists and internists. There are a number of side effects and, like any drug, will have its limitations. But Palladia is a huge step in the right direction for curing this horrible disease.